Scinai Immunotherapeutics Ltd.

SCNI Nasdaq SEC CIK 1611747
Follow Scinai Immunotherapeutics Ltd. Weekly email: filings, results

Financials

Reported figures only · latest: Q4 2025 USD · US GAAP
EPS, diluted -

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income6 fiscal years
−$10M−$5M$0$5MFY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$8.3M
FY24$4.8M
FY23-
FY22-
FY21−$8.2M
FY20-
Free cash flowOperating cash flow minus capital expenditure
−$15M−$10M−$5M$0FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$6.1M
FY24−$6.3M
FY23−$10M
FY22−$8.1M
FY21−$7.6M
FY20-